Doximity Is Up 31% on a Guidance Raise. Has the AI Bull Case Really Changed?

The post-earnings rerating shifted the question

After a premarket jump from $20.66 to $38.87 and a roughly 33% surge in the first full session, DOCS is no longer being judged only on whether its base business is "decent." The market is now asking a sharper question: can AI adoption turn into revenue quickly enough to support a higher multiple?

Management gave that debate fresh fuel by raising fiscal-2027 revenue guidance to $671 million-$681 million, citing early AI Search traction. Raised guidance after a gap-up does not settle the debate; it tightens the timeline. Investors now need evidence that engagement can convert into dollars before expectations get too far ahead.

The operating case still has legs. Doximity highlighted workflow active prescriber growth of more than 30% year over year, AI Search query growth exceeding 25% quarter over quarter, and a platform with more than 3 million members. The distribution is there. What remains to be proven is how fast that reach becomes revenue.

AI adoption looks real, but monetization is still the proof point

The guidance raise matters because it moves Doximity's AI story from possibility to pipeline. Management is not asking investors to imagine a new wedge from scratch. It is saying that usage is already showing up inside physician workflows, and the next question is whether that usage converts into dollars fast enough to justify the rerating.

Usage signals are credible

The latest operating data supports that view. Workflow prescribers grew more than 30% year over year, while AI Search queries rose more than 25% quarter over quarter. That combination matters: prescriber growth points to expanding reach inside the workflow, while query growth suggests heavier use among existing users.

A Doximity-commissioned survey of 3,151 physicians also found 94% are currently using AI or are interested in doing so. That does not prove monetization, but it does suggest the audience is already engaged and centrally located on the platform.

Accuracy matters in clinical AI, and management said Doximity's model posted a 4.8% error rate versus 13.6% for Anthropic's best model in physician-focused testing. That could be a meaningful differentiator, though it should still be treated as management's claim rather than independently verified proof.

What could fool bulls

The key split is simple: adoption is a signal, but dollars are the proof. Management tied the guidance raise to early AI product traction, not to a mature AI revenue run rate. In other words, the engine may be firing, but the revenue evidence is still early.

Watch for these proof points over the next one to two quarters: - AI revenue becomes visible enough to support the raised fiscal-2027 revenue range of $671 million to $681 million - AI Search query growth exceeding 25% quarter over quarter remains strong or improves - demand remains durable through continued customer and program onboarding - higher AI usage starts showing up more clearly in revenue, not just engagement

Profitability gave Doximity room to rerate, but less room for error

What the market rewarded was not just a decent quarter. It rewarded evidence that Doximity can keep investing in AI without breaking its earnings engine. In the latest quarter, the company delivered $156.6 million of revenue, up 7.0% year over year, while producing a 47.7% margin on adjusted EBITDA. That is the core moat in plain view: a software-heavy healthcare network still generating strong operating leverage during an AI buildout.

The margins improved the story, but they did not remove the risk

Bulls can fairly argue that the core business is holding up while AI gets funded. At the same time, Adjusted EBITDA declined to $74.8 million, a 47.7% margin compared with $79.8 million and a 54.7% margin a year earlier, and GAAP net income fell to $24.3 million from $53.3 million. That decline is real. It looks more like investment drag than demand failure, but after a sharp rerating, investors are less likely to shrug it off.

What has changed is the market's tolerance for ambiguity. The raised outlook matters, but so does execution speed. From here, investors need to see: - revenue continue moving up from $156.6 million of revenue, with AI revenue becoming more than an early signal - margins remain resilient, even if they do not immediately snap back to last year's level - monetization show up before expectations price out any disappointment

Last year, Doximity was hit hard when next quarter's revenue guidance was below analyst estimates and management flagged shorter-term spending commitments from clients. Today, the stock can likely absorb a small miss. It may have less tolerance for another quarter where adoption rises but dollars lag.

Bull case is stronger, but the stock is now an execution watchlist

After the premarket jump from $20.66 to $38.87 and a guidance raise tied to early AI Search traction, Doximity is no longer a cheap narrative. It is now an execution watchlist. The strongest part of the setup remains intact: AI demand is appearing inside a large physician network with more than 3 million members, not in some speculative side project.

The next catalyst window is obvious. Analysts are now looking for AI revenue to become a meaningful growth driver in the third quarter, which makes the next earnings cycle the real verdict.

Watch for these signals: - AI revenue starts showing up clearly enough to support the raised fiscal-2027 revenue guidance - Momentum holds after the sharp post-earnings rally - Adoption remains broad among physicians already using AI or interested in doing so

Invalidation cues: - A repeat of the old failure mode, where next quarter's revenue guidance was below analyst estimates - Usage stays strong but monetization remains unclear - The stock loses the higher multiple once the narrative fades

The bull case is stronger, but the setup is now stricter. DOCS looks less like a "buy the story" stock and more like a watchlist name where the next leg higher needs visible revenue conversion.